"The important thing is to never stop questioning."
— Albert Einstein
Find concise answers to common questions and access key materials about Aleva’s technology, studies, and partnership opportunities.
Find concise answers to common questions and access key materials about Aleva’s technology, studies, and partnership opportunities.
Technology & Design
What makes Aleva’s DBS technology unique?
What makes Aleva’s DBS technology unique?
Aleva developed the first truly directional Deep Brain Stimulation (DBS) system, using proprietary MEMS-based thin-film electrodes that are smaller, smoother, and more precise than traditional laser-cut designs.
How does directional stimulation improve therapy?
How does directional stimulation improve therapy?
By using 12 independent directional contacts per lead, Aleva’s system can shape and steer stimulation precisely toward the therapeutic target, reducing unwanted side effects.
What is MEMS technology, and why does it matter?
What is MEMS technology, and why does it matter?
MEMS (Micro-Electro-Mechanical Systems) fabrication allows Aleva to align electrodes and wiring simultaneously during production, enabling ultra-thin, reliable, and high-precision electrodes with fewer artefacts and greater biocompatibility.
Why is Aleva’s implantable pulse generator different?
Why is Aleva’s implantable pulse generator different?
The directSTIM system integrates a 24-channel pulse generator—an industry benchmark—that delivers fully independent current sources for individualised therapy, combined with one of the smallest rechargeable IPGs on the market.
Can Aleva’s system be used safely with MRI or CT scans?
Can Aleva’s system be used safely with MRI or CT scans?
Yes. Aleva’s rounded electrodes and MEMS construction generate minimal MRI/CT artefacts, providing safer pre- and post-operative imaging and better surgical planning.
Clinical Outcomes
What clinical evidence supports Aleva’s technology?
What clinical evidence supports Aleva’s technology?
The CE-marked directSTIM system demonstrated a 51% symptom improvement and a 58% medication reduction in Parkinson’s patients six months after implantation in an ongoing European PMCF study.
How widely has Aleva’s DBS system been used?
How widely has Aleva’s DBS system been used?
It has been implanted in patients across multiple European centres of excellence, with adoption confirmed by leading neurologists and neurosurgeons in 16 hospitals across 8 countries.
Is Aleva’s DBS therapy reversible?
Is Aleva’s DBS therapy reversible?
Yes. DBS is a reversible therapy. The system can be turned off or removed, preserving future treatment options.
How does Aleva compare to existing treatments?
How does Aleva compare to existing treatments?
Clinical data show Aleva’s directional DBS offers superior long-term outcomes versus medication alone, improving quality of life and reducing side effects.
Is Aleva conducting further clinical studies?
Is Aleva conducting further clinical studies?
Yes. A post-market follow-up study in the EU is ongoing, and a PMA study is planned in the United States. Additional trials are in preparation for new indications such as OCD and Essential Tremor.
Intellectual Property
How extensive is Aleva’s IP portfolio?
How extensive is Aleva’s IP portfolio?
Aleva holds over 120 granted patents across 13 families covering all major elements of its DBS platform, from MEMS electrode design to cortical stimulation and recording technologies.
What gives Aleva its technological lead?
What gives Aleva its technological lead?
The company’s MEMS-based electrode design and proprietary thin-film process are unmatched in the industry, giving Aleva an estimated five-year head start in manufacturing precision and miniaturisation.
Has Aleva published its research?
Has Aleva published its research?
Yes. Aleva was the first company to demonstrate directional brain stimulation in humans, published in Brain (Oxford Academic, 2014), and continues to be cited in key neuromodulation journals.
How durable are Aleva’s electrodes?
How durable are Aleva’s electrodes?
BioMEMS longevity testing has proven electrode robustness under extreme stimulation for up to 15 years—evidence supporting the long-term reliability of Aleva’s implants.
Does Aleva’s IP cover other neurological indications?
Does Aleva’s IP cover other neurological indications?
Yes. Patent coverage extends beyond Parkinson’s and Essential Tremor to include epilepsy, OCD, and cortical stimulation.
Your questions,
Answered
Didn’t find your answer? Send Aleva an email or visit our contact page:
Market Positioning & Investment Signals
Where is Aleva based?
Where is Aleva based?
Aleva is headquartered at the EPFL Innovation Park in Lausanne, Switzerland—one of Europe’s leading centres for neurotechnology and microengineering.
Who has invested in Aleva?
Who has invested in Aleva?
The company has raised around €70–75 M from BioMedPartners, Kinled Holding, and several international family offices, with a historic private valuation peak of €140 M.
What is Aleva’s current strategic focus?
What is Aleva’s current strategic focus?
Aleva is repositioning from a Parkinson’s-only focus to a broader licensing and partnership model—expanding its DBS technology into new neurological indications and geographies.
Is Aleva open to licensing or acquisition?
Is Aleva open to licensing or acquisition?
Yes. Aleva’s patented neuromodulation platform and validated clinical data are available for licensing, co-development, or acquisition opportunities.
What markets show the strongest growth potential for Aleva?
What markets show the strongest growth potential for Aleva?
The global DBS market is projected to triple from €1.4 B in 2022 to €4.2 B by 2030, with growing adoption in both established and emerging regions such as Asia and the Middle East.
Technology & Design
What makes Aleva’s DBS technology unique?
What makes Aleva’s DBS technology unique?
Aleva developed the first truly directional Deep Brain Stimulation (DBS) system, using proprietary MEMS-based thin-film electrodes that are smaller, smoother, and more precise than traditional laser-cut designs.
How does directional stimulation improve therapy?
How does directional stimulation improve therapy?
By using 12 independent directional contacts per lead, Aleva’s system can shape and steer stimulation precisely toward the therapeutic target, reducing unwanted side effects.
What is MEMS technology, and why does it matter?
What is MEMS technology, and why does it matter?
MEMS (Micro-Electro-Mechanical Systems) fabrication allows Aleva to align electrodes and wiring simultaneously during production, enabling ultra-thin, reliable, and high-precision electrodes with fewer artefacts and greater biocompatibility.
Why is Aleva’s implantable pulse generator different?
Why is Aleva’s implantable pulse generator different?
The directSTIM system integrates a 24-channel pulse generator—an industry benchmark—that delivers fully independent current sources for individualised therapy, combined with one of the smallest rechargeable IPGs on the market.
Can Aleva’s system be used safely with MRI or CT scans?
Can Aleva’s system be used safely with MRI or CT scans?
Yes. Aleva’s rounded electrodes and MEMS construction generate minimal MRI/CT artefacts, providing safer pre- and post-operative imaging and better surgical planning.
Clinical Outcomes
What clinical evidence supports Aleva’s technology?
What clinical evidence supports Aleva’s technology?
The CE-marked directSTIM system demonstrated a 51% symptom improvement and a 58% medication reduction in Parkinson’s patients six months after implantation in an ongoing European PMCF study.
How widely has Aleva’s DBS system been used?
How widely has Aleva’s DBS system been used?
It has been implanted in patients across multiple European centres of excellence, with adoption confirmed by leading neurologists and neurosurgeons in 16 hospitals across 8 countries.
Is Aleva’s DBS therapy reversible?
Is Aleva’s DBS therapy reversible?
Yes. DBS is a reversible therapy. The system can be turned off or removed, preserving future treatment options.
How does Aleva compare to existing treatments?
How does Aleva compare to existing treatments?
Clinical data show Aleva’s directional DBS offers superior long-term outcomes versus medication alone, improving quality of life and reducing side effects.
Is Aleva conducting further clinical studies?
Is Aleva conducting further clinical studies?
Yes. A post-market follow-up study in the EU is ongoing, and a PMA study is planned in the United States. Additional trials are in preparation for new indications such as OCD and Essential Tremor.
Intellectual Property
How extensive is Aleva’s IP portfolio?
How extensive is Aleva’s IP portfolio?
Aleva holds over 120 granted patents across 13 families covering all major elements of its DBS platform, from MEMS electrode design to cortical stimulation and recording technologies.
What gives Aleva its technological lead?
What gives Aleva its technological lead?
The company’s MEMS-based electrode design and proprietary thin-film process are unmatched in the industry, giving Aleva an estimated five-year head start in manufacturing precision and miniaturisation.
Has Aleva published its research?
Has Aleva published its research?
Yes. Aleva was the first company to demonstrate directional brain stimulation in humans, published in Brain (Oxford Academic, 2014), and continues to be cited in key neuromodulation journals.
How durable are Aleva’s electrodes?
How durable are Aleva’s electrodes?
BioMEMS longevity testing has proven electrode robustness under extreme stimulation for up to 15 years—evidence supporting the long-term reliability of Aleva’s implants.
Does Aleva’s IP cover other neurological indications?
Does Aleva’s IP cover other neurological indications?
Yes. Patent coverage extends beyond Parkinson’s and Essential Tremor to include epilepsy, OCD, and cortical stimulation.
Your questions,
Answered
Didn’t find your answer? Send Aleva an email or visit our contact page:
Market Positioning & Investment Signals
Where is Aleva based?
Where is Aleva based?
Aleva is headquartered at the EPFL Innovation Park in Lausanne, Switzerland—one of Europe’s leading centres for neurotechnology and microengineering.
Who has invested in Aleva?
Who has invested in Aleva?
The company has raised around €70–75 M from BioMedPartners, Kinled Holding, and several international family offices, with a historic private valuation peak of €140 M.
What is Aleva’s current strategic focus?
What is Aleva’s current strategic focus?
Aleva is repositioning from a Parkinson’s-only focus to a broader licensing and partnership model—expanding its DBS technology into new neurological indications and geographies.
Is Aleva open to licensing or acquisition?
Is Aleva open to licensing or acquisition?
Yes. Aleva’s patented neuromodulation platform and validated clinical data are available for licensing, co-development, or acquisition opportunities.
What markets show the strongest growth potential for Aleva?
What markets show the strongest growth potential for Aleva?
The global DBS market is projected to triple from €1.4 B in 2022 to €4.2 B by 2030, with growing adoption in both established and emerging regions such as Asia and the Middle East.
Request Aleva's Latest Presentation
What makes Aleva’s DBS technology unique?
What makes Aleva’s DBS technology unique?
Aleva developed the first truly directional Deep Brain Stimulation (DBS) system, using proprietary MEMS-based thin-film electrodes that are smaller, smoother, and more precise than traditional laser-cut designs.
How does directional stimulation improve therapy?
How does directional stimulation improve therapy?
By using 12 independent directional contacts per lead, Aleva’s system can shape and steer stimulation precisely toward the therapeutic target, reducing unwanted side effects.
What is MEMS technology, and why does it matter?
What is MEMS technology, and why does it matter?
MEMS (Micro-Electro-Mechanical Systems) fabrication allows Aleva to align electrodes and wiring simultaneously during production, enabling ultra-thin, reliable, and high-precision electrodes with fewer artefacts and greater biocompatibility.
Why is Aleva’s implantable pulse generator different?
Why is Aleva’s implantable pulse generator different?
The directSTIM system integrates a 24-channel pulse generator—an industry benchmark—that delivers fully independent current sources for individualised therapy, combined with one of the smallest rechargeable IPGs on the market.
Can Aleva’s system be used safely with MRI or CT scans?
Can Aleva’s system be used safely with MRI or CT scans?
Yes. Aleva’s rounded electrodes and MEMS construction generate minimal MRI/CT artefacts, providing safer pre- and post-operative imaging and better surgical planning.
Your questions,
Answered
Didn’t find your answer? Send Aleva an email or visit our contact page: